# The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis

SUPPLEMENTARY MATERIALS

Supplementary Figure 1: The forest plot of alopecia in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Supplementary Figure 2: The forest plot of fatigue in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.


Supplementary Figure 3: The forest plot of nausea in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Study or Subgroup	Anti-PD1/PD-L1 Events	Total	Chemotherapy Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
CheckMate 017,2015	10	131	26	129	10.6%	0.33 [0.15, 0.71]
CheckMate 057,2015	22	287	62	268	17.2%	0.28 [0.16, 0.46]
KEYNOTE-010,2016a	24	339	56	309	17.7%	0.34 [0.21, 0.57]
KEYNOTE-010,2016b	22	343	56	309	17.2%	0.31 [0.18, 0.52]
OAK,2016	94	609	141	578	26.4%	0.57 [0.42, 0.76]
POPLAR,2016	10	142	30	135	10.9%	0.27 [0.12, 0.57]
Total (95% CI)		1851		1728	100.0%	0.36 [0.27, 0.49]
Total events	182		371			

Heterogeneity: Tau² = 0.07; Chi² = 10.10, df = 5 (P = 0.07); I² = 50%
Test for overall effect: Z = 6.64 (P < 0.00001)

Favours Anti-PD1/PD-L1   Favours Chemotherapy

Supplementary Figure 4: The forest plot of diarrhea in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Study or Subgroup	Anti-PD1/PD-L1 Events	Total	Chemotherapy Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
CheckMate 017,2015	2	131	28	129	9.2%	0.06 [0.01, 0.24]
CheckMate 057,2015	6	287	53	268	15.6%	0.09 [0.04, 0.21]
KEYNOTE-010,2016a	10	339	40	309	17.7%	0.20 [0.10, 0.42]
KEYNOTE-010,2016b	14	343	40	309	18.8%	0.29 [0.15, 0.54]
OAK,2016	70	609	136	578	22.9%	0.42 [0.31, 0.58]
POPLAR,2016	8	142	22	135	15.8%	0.31 [0.13, 0.72]
Total (95% CI)		1851		1728	100.0%	0.21 [0.12, 0.37]
Total events	110		319			

Heterogeneity: Tau² = 0.33; Chi² = 19.31, df = 5 (P = 0.002); I² = 74%
Test for overall effect: Z = 5.42 (P < 0.00001)

Favours Anti-PD1/PD-L1   Favours Chemotherapy

Supplementary Figure 5: The forest plot of anemia in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
CheckMate 017,2015	14	131	25	129	9.7%	0.50 [0.25, 1.01]
CheckMate 057,2015	30	287	42	268	15.6%	0.63 [0.38, 1.04]
KEYNOTE-010,2016a	46	339	49	309	18.4%	0.83 [0.54, 1.29]
KEYNOTE-010,2016b	33	343	49	309	16.8%	0.56 [0.35, 0.90]
OAK,2016	143	609	136	578	28.1%	1.00 [0.76, 1.30]
POPLAR,2016	25	142	21	135	11.3%	1.16 [0.61, 2.19]
Total (95% CI)		1851		1728	100.0%	0.78 [0.60, 1.00]
Total events	291		322			

Heterogeneity: Tau² = 0.04; Chi² = 8.61, df = 5 (P = 0.13); I² = 42%
Test for overall effect: Z = 1.98 (P = 0.05)

Favours Anti-PD1/PD-L1   Favours Chemotherapy

Supplementary Figure 6: The forest plot of decreased appetite in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Odds Ratio M-H, Random, 95% CI
CheckMate 017,2015	13	131	18	129	11.7%	0.68 [0.32, 1.45]
CheckMate 057,2015	29	287	47	268	18.8%	0.53 [0.32, 0.87]
KEYNOTE-010,2016a	20	339	35	309	16.4%	0.49 [0.28, 0.87]
KEYNOTE-010,2016b	19	343	35	309	16.1%	0.46 [0.26, 0.82]
OAK,2016	116	609	114	578	26.7%	0.96 [0.72, 1.28]
POPLAR,2016	9	142	18	135	10.3%	0.44 [0.19, 1.02]
Total (95% CI)		1851		1728	100.0%	0.60 [0.44, 0.83]
Total events	206		267			

Heterogeneity: Tau² = 0.08; Chi² = 10.45, df = 5 (P = 0.06); I² = 52%
Test for overall effect: Z = 3.07 (P = 0.002)

Favours [experimental]   Favours [control]

Supplementary Figure 7: The forest plot of asthenia in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Supplementary Figure 8: The forest plot of vomiting in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Supplementary Figure 9: The forest plot of neutropenia in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Supplementary Figure 10: The forest plot of hyperthyroidism in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.

Supplementary Figure 11: The forest plot of hypothyroidism in advanced NSCLC patients who received anti-PD1/PD-L1 antibody therapy compared to docetaxel.